{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-217619","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.276699+00:00","generated_at":"2026-05-31T05:13:36.890570+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aura reports positive Phase 2 bel-sar results: 80% tumor control, 90% vision preservation","bullets":["Bel-sar achieved 80% tumor control rate in Phase 3-eligible patients (8/10); complete cessation of growth post-treatment.","Visual acuity preserved in 90% of 10 patients; 80% had high-risk tumors near fovea/optic disc.","No treatment-related serious adverse events; mild Grade 1 ocular AEs self-limited, resolved in median 6 days.","FDA agreed under Special Protocol Assessment for Phase 3 CoMpass trial; enrollment ongoing.","Virtual investor event today at 8:00 am ET featuring key opinion leaders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-217619","json":"https://secwatch.observer/filing/0001193125-24-217619.json","markdown":"https://secwatch.observer/filing/0001193125-24-217619.md","text":"https://secwatch.observer/filing/0001193125-24-217619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524217619/0001193125-24-217619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524217619/d886516d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:13:36.890570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}